Current and future therapeutic approaches for the treatment of follicular lymphoma

References

• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s lymphoma classification project. Ann Oncol. 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood. 2012;120:2553–2561.
   PubMed Web of Science ®Google Scholar
• Zamò A, Pischimarov J, Schlesner M, et al. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. Leukemia. 2017 Aug 21. DOI:10.1038/leu.2017.270
   PubMed Web of Science ®Google Scholar
• Kishimoto W, Nishikori M. Molecular pathogenesis of follicular lymphoma. J Clin Exp Hematop. 2014;54(1):23–30.
   PubMedGoogle Scholar
• Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014 May 1;32(13):1347–1355.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva, Switzerland: WHO Press; 2008.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–1122.
   PubMed Web of Science ®Google Scholar
• Huet S, Tesson B, Jais J, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;S1470-2045(18):30102–30105.
   Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes for the non-Hodgkin’s lymphoma classification project. J Clin Oncol. 1998;16(8):2780–2795.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Ciammella P, Ricardi U. Limited stage follicular lymphoma: current role of radiation therapy. Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016041.
   PubMedGoogle Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117.
   PubMed Web of Science ®Google Scholar
• Friedberg J, Huang J, Dillon H, et al. Initial therapeutic strategy in follicular lymphoma: an analysis from the national lymphocare study. J Clin Oncol. 2006;24:428s.
   Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522.
   Google Scholar
• Sungalee S, Mamessier E, Morgado E, et al. Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. J Clin Invest. 2014;124(12):5337–5351.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22–33.
   PubMed Web of Science ®Google Scholar
• Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424–3431.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. Leukemia 2003;17(12):2257-2317.
   Google Scholar
• von Neuhoff N, Dreger P, Suttorp M, et al. Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma. Bone Marrow Transplant. 1998;22(2):161–166.
   PubMed Web of Science ®Google Scholar
• Weinberg OK, Ai WZ, Mariappan MR, et al. “Minor” BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn. 2007;9(4):530–537.
   PubMed Web of Science ®Google Scholar
• Cavalli M, De Novi LA, Della Starza I, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol. 2017;177(4):588–596.
   PubMed Web of Science ®Google Scholar
• Drandi D, Kubiczkova-Besse L, Ferrero S, et al. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn. 2015;17(6):652–660.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Luminari S, Ciabatti E, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20(24):6398–6405.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Starza ID, Frattarelli N, et al. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. Br J Haematol. 2007;137(3):216–220.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Broussais-Guillaumot F, Chetaille B, et al. Nature and importance of follicular lymphoma precursors. Haematologica. 2014;99(5):802–810.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Clinical practice guidelines. Annuals Oncol. 2016;27:v83–v90.
   PubMed Web of Science ®Google Scholar
• Wohrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2016;17:780–784.
   Google Scholar
• Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL 05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108–2112.
   PubMed Web of Science ®Google Scholar
• Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:2307–2314.
   PubMed Web of Science ®Google Scholar
• Perry C, Lerman H, Joffè L, et al. The value of PET/CT in detecting bone marrow involvement in patients with follicular lymphoma. Medicine. 2016;95(9):e2910.
   PubMed Web of Science ®Google Scholar
• Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicentre studies. J Clin Oncol. 2016 Aug 22:pii: JCO669440. [Epub ahead of print].
   Web of Science ®Google Scholar
• Trotman J, Fournier M, Lamy T, et al. Positron emission tomography computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194–3200.
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442–447.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [18F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–4322.
   PubMed Web of Science ®Google Scholar
• Paryani SB, Hoppe RT. Cox RSet al. Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer. 1983;52(12):2300–2307.
   PubMed Web of Science ®Google Scholar
• Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret hospital experience. Int J Radiat Oncol Biol Phys. 1984;10:489–497.
   PubMed Web of Science ®Google Scholar
• Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin’ s lymphoma: long-term follow-up of patients treated by the British national lymphoma investigation with radiotherapy alone as initial therapy. Br J Canc. 1996;69:1088–1093.
   Web of Science ®Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Stuschke M, Hoederath A, Sack H, et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Cancer. 1997;80:2273–2284.
   PubMed Web of Science ®Google Scholar
• Neumann H, Blanck H, Koch R, et al. Follicle centre lymphoma: treatment results for stage I and II. Strahlenther Onkol. 2003;179(12):840–846.
   PubMed Web of Science ®Google Scholar
• Petersen PM, Gospodarowicz MK, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol. 2004;22(14s):652.
   Google Scholar
• Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51(5):1219–1227.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the national lymphocare study. J Clin Oncol. 2012;30:3368–3375.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116(16):3843–3851.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106(12):3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–4586.
   PubMed Web of Science ®Google Scholar
• Herold M, Dölken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin’s lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol. 2003;82(2):77–79.
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56:2350–2356.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Wasle I, et al. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? Anticancer Res. 2014;34(11):6701–6704.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83–v90.
   PubMed Web of Science ®Google Scholar
• Reynders K, Illidge T, Siva S, et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503–510.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.
   PubMed Web of Science ®Google Scholar
• Cencini E, Puccini B, Rigacci L, et al. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. Leuk Lymphoma. 2018;59(6):1420-1426.
   Google Scholar
• Ruella M, Filippi AR, Bruna R, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94(4):783–791.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Della Starza ID, Cappelli LV, et al. Early stage follicular lymphoma. predictive role of Minimal Residual Disease (MRD) and impact of mrd-driven treatment with radiotherapy and rituximab on clinical outcome. Blood. 2016;128:2959.
   Web of Science ®Google Scholar
• Horning SJ. Rosenberg SA: the natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475, 198424.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non- Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516–522.
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–106.
   PubMed Web of Science ®Google Scholar
• Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23:2380–2385.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30:3848–3853.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424–435.
   PubMed Web of Science ®Google Scholar
• Federico M, Caballero D, Marcheselli L, et al. The risk of transformation of follicular lymphoma “transformed” by rituximab: the ARISTOTLE study promoted by the European Lymphoma Institute. Hematol Oncol. 2017;35(S2):115–116.
   Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol. 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824–4831.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–1513.
   PubMed Web of Science ®Google Scholar
• Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;1;36(7):689–696.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Willenbacher W, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016 Jun;95(7):1107–1114.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Feugier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immuno-chemotherapy. Blood. 2013;223:a50.
   Google Scholar
• Kahl BS, Burke JM, van der Jagt R, et al. Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial. Blood. 2017;130:484.
   Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010 Jan 1;116(1):106–114.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012 Apr 19;119(16):3698–3704.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 Mar 27:JCO.2017.76.365.
   Google Scholar
• Gyan E, Foussard C, Bertrand P, et al. High-dosetherapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patient with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113:995–1001.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German low-grade lymphoma study group. Blood. 2004;104:2667–2674.
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108:2540–2544.
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–4013.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516–2522.
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Canals C, Luang JJ, et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the lymphoma working party of the EBMT. Bone Marrow Transplant. 2013;48:1409–1414.
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E, Bacher U, Kroger NM, et al. Reduced-intensity allografting as first transplantation approach in relapsed/refractorygrades one and twofollicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transplant. 2015;21:2091–2099.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the lymphoma working party of the EBMT. Ann Oncol. 2016;27:1088–1094.
   Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Martin P, Jung S-H, Pitcher B, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017;28:2806–2812.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375–381.
   PubMed Web of Science ®Google Scholar
• Leonard J-P, Jung S-H, Johnson J, et al. Lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–3640.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Le Gouill S, Feugier P, et al. A phase II LYSA study of obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma. Hematol Oncol. 2017;35:52–53.
   Google Scholar
• Advani R-H, Buggy -J-J, Sharman J-P, et al. Bruton tyrosine kinase inhibitor (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2012;31:88–94.
   PubMed Web of Science ®Google Scholar
• Bartlett N-L, Costello B-A, LaPlant B-R, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 CONSORTIUM trial. Blood. 2018;131(2):182–190.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037–3039.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher B, Jung S, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood. 2014;124:3091.
   Web of Science ®Google Scholar
• Scott WJ, Hentemann MF, Rowley RB, et al. Discovery and SAR of novel 2,3-dihydroimidazo[1,2- c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem. 2016;11:1517–1530.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905.
   PubMed Web of Science ®Google Scholar
• Zinzani P, Wagner-Johnston N, Miller C, et al. DYNAMO: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double-refractory indolent non-Hodgkin lymphoma. Hematol Oncol. 2017;35(S2):69–70.
   PubMedGoogle Scholar
• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846.56.
   Web of Science ®Google Scholar
• Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68-83.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 7519-7519.
   Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Schuster JS, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. New Engl J Med. 2017;377(26):2545–2554.
   PubMed Web of Science ®Google Scholar
• Subramanian J, Cavenagh J, Desai B, et al. Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. Cancer Manag Res. 2017;9:131–140.
   PubMed Web of Science ®Google Scholar
• Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362–e373.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Ilidia M, Govindbabu KS, et al. A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in patients with previously untreated advanced follic treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter phase II trial-MIR trial. ClinicalTrial NCT01419665.
   Google Scholar